Vaccinex Trials - LARVOL Sigma

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

pepinemab (VX15) / Vaccinex

NCT03320330: Pepinemab in Treating Younger Patients With Recurrent, Relapsed, or Refractory Solid Tumors

Completed

1/2

Laboratory Biomarker Analysis, Pepinemab, moAb VX15/2503, VX15/2503, Pharmacological Study

Children's Oncology Group, National Cancer Institute (NCI)

Recurrent Malignant Solid Neoplasm, Recurrent Osteosarcoma, Refractory Malignant Solid Neoplasm, Refractory Osteosarcoma

12/20

06/24

NCT03205644: VX15/2503 in Treating Younger Patients With Recurrent, Relapsed, or Refractory Solid Tumors

Not yet recruiting

1/2

Anti-SEMA4D Monoclonal Antibody VX15/2503, moAb VX15/2503, VX15/2503, Laboratory Biomarker Analysis, Pharmacological Study

Children's Oncology Group, National Cancer Institute (NCI), COG Phase I Consortium

Recurrent Malignant Solid Neoplasm, Recurrent Osteosarcoma, Refractory Malignant Solid Neoplasm

09/21

10/21

SIGNAL-AD, NCT04381468: SEMA4D Blockade Safety and Brain Metabolic Activity in Alzheimer's Disease (AD)

Completed

1/2

Pepinemab, Placebo

Vaccinex Inc., Alzheimer's Drug Discovery Foundation, Alzheimer's Association

Alzheimer Disease

06/24

KEYNOTE B84, NCT04815720: Pepinemab in Combination With Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

	P1b data in combination with pepinemab for recurrent or metastatic HNSCC
	Apr 2022 - Apr 2022: P1b data in combination with pepinemab for recurrent or metastatic HNSCC

Completed

1/2

pepinemab + pembrolizumab, KEYTRUDA®

Vaccinex Inc., Merck Sharp & Dohme LLC

Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC)

07/24

NCT05102721: Trial of Immunotherapy With Avelumab and Pepinemab As Second Line For Patients With Metastatic Pancreatic Adenocarcinoma

Active, not recruiting

1/2

Avelumab and Pepinemab

Vaccinex Inc., University of Rochester

Metastatic Pancreatic Adenocarcinoma

12/28

NCT03373188: VX15/2503 and Immunotherapy in Resectable Pancreatic and Colorectal Cancer

Completed

Anti-SEMA4D Monoclonal Antibody VX15/2503, moAb VX15/2503, VX15/2503, Ipilimumab, BMS-734016, MDX-010, MDX-CTLA4, Yervoy, Nivolumab, BMS-936558, MDX-1106, NIVO, ONO-4538, Opdivo, Surgery

Emory University, Vaccinex Inc., National Cancer Institute (NCI), National Institutes of Health (NIH)

Colon Carcinoma Metastatic in the Liver, Colorectal Adenocarcinoma, Pancreatic Adenocarcinoma, Resectable Pancreatic Carcinoma, Stage I Pancreatic Cancer, Stage IA Pancreatic Cancer, Stage IB Pancreatic Cancer, Stage II Pancreatic Cancer, Stage IIA Pancreatic Cancer, Stage IIB Pancreatic Cancer, Stage III Pancreatic Cancer, Stage IV Colorectal Cancer, Stage IVA Colorectal Cancer, Stage IVB Colorectal Cancer

10/21

NCT03769155: VX15/2503 With or Without Ipilimumab and/or Nivolumab in Patients With Resectable Stage IIIB-D Melanoma

Active, not recruiting

Ipilimumab, BMS-734016, MDX-010, MDX-CTLA4, Yervoy, Nivolumab, BMS-936558, MDX-1106, NIVO, ONO-4538, Opdivo, VX15/2503, moAb VX15/2503, Pepinemab, Surgery

Emory University, Bristol-Myers Squibb, Vaccinex Inc., National Institutes of Health (NIH), National Cancer Institute (NCI)

Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8

12/23

12/32

NCT05378464: Adoptive T Cell Therapy Following HER2-Pulsed Dendritic Cell Vaccine & Pepinemab /Trastuzumab in Patients w/ Metastatic HER2+ Breast Cancer

Recruiting

Dendritic Cell (DC1) Vaccine, Trastuzumab, Herceptin, Trazimera, Pepinemab, T-Cell therapy

H. Lee Moffitt Cancer Center and Research Institute, Vaccinex Inc.

HER2-positive Breast Cancer

12/25

12/26

NCT03690986: VX15/2503 in Combination with Ipilimumab or Nivolumab in Patients with Head and Neck Cancer

Recruiting

VX15/2503, moAb VX15/2503, Anti-SEMA4D Monoclonal Antibody VX15/2503, Pepinemab, Ipilimumab, BMS-734016, MDX-010, MDX-CTLA4, Yervoy, Nivolumab, BMS-936558, MDX-1106, NIVO, ONO-4538, Opdivo

Emory University, Vaccinex Inc.

Squamous Cell Carcinoma of the Head and Neck

06/25

11/25

VX35 / Vaccinex

No trials found

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

pepinemab (VX15) / Vaccinex

NCT03320330: Pepinemab in Treating Younger Patients With Recurrent, Relapsed, or Refractory Solid Tumors

Completed

1/2

Laboratory Biomarker Analysis, Pepinemab, moAb VX15/2503, VX15/2503, Pharmacological Study

Children's Oncology Group, National Cancer Institute (NCI)

Recurrent Malignant Solid Neoplasm, Recurrent Osteosarcoma, Refractory Malignant Solid Neoplasm, Refractory Osteosarcoma

12/20

06/24

NCT03205644: VX15/2503 in Treating Younger Patients With Recurrent, Relapsed, or Refractory Solid Tumors

Not yet recruiting

1/2

Anti-SEMA4D Monoclonal Antibody VX15/2503, moAb VX15/2503, VX15/2503, Laboratory Biomarker Analysis, Pharmacological Study

Children's Oncology Group, National Cancer Institute (NCI), COG Phase I Consortium

Recurrent Malignant Solid Neoplasm, Recurrent Osteosarcoma, Refractory Malignant Solid Neoplasm

09/21

10/21

SIGNAL-AD, NCT04381468: SEMA4D Blockade Safety and Brain Metabolic Activity in Alzheimer's Disease (AD)

Completed

1/2

Pepinemab, Placebo

Vaccinex Inc., Alzheimer's Drug Discovery Foundation, Alzheimer's Association

Alzheimer Disease

06/24

KEYNOTE B84, NCT04815720: Pepinemab in Combination With Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

	P1b data in combination with pepinemab for recurrent or metastatic HNSCC
	Apr 2022 - Apr 2022: P1b data in combination with pepinemab for recurrent or metastatic HNSCC

Completed

1/2

pepinemab + pembrolizumab, KEYTRUDA®

Vaccinex Inc., Merck Sharp & Dohme LLC

Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC)

07/24

NCT05102721: Trial of Immunotherapy With Avelumab and Pepinemab As Second Line For Patients With Metastatic Pancreatic Adenocarcinoma

Active, not recruiting

1/2

Avelumab and Pepinemab

Vaccinex Inc., University of Rochester

Metastatic Pancreatic Adenocarcinoma

12/28

NCT03373188: VX15/2503 and Immunotherapy in Resectable Pancreatic and Colorectal Cancer

Completed

Anti-SEMA4D Monoclonal Antibody VX15/2503, moAb VX15/2503, VX15/2503, Ipilimumab, BMS-734016, MDX-010, MDX-CTLA4, Yervoy, Nivolumab, BMS-936558, MDX-1106, NIVO, ONO-4538, Opdivo, Surgery

Emory University, Vaccinex Inc., National Cancer Institute (NCI), National Institutes of Health (NIH)

10/21

NCT03769155: VX15/2503 With or Without Ipilimumab and/or Nivolumab in Patients With Resectable Stage IIIB-D Melanoma

Active, not recruiting

Ipilimumab, BMS-734016, MDX-010, MDX-CTLA4, Yervoy, Nivolumab, BMS-936558, MDX-1106, NIVO, ONO-4538, Opdivo, VX15/2503, moAb VX15/2503, Pepinemab, Surgery

Emory University, Bristol-Myers Squibb, Vaccinex Inc., National Institutes of Health (NIH), National Cancer Institute (NCI)

Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID Cutaneous Melanoma AJCC v8

12/23

12/32

NCT05378464: Adoptive T Cell Therapy Following HER2-Pulsed Dendritic Cell Vaccine & Pepinemab /Trastuzumab in Patients w/ Metastatic HER2+ Breast Cancer

Recruiting

Dendritic Cell (DC1) Vaccine, Trastuzumab, Herceptin, Trazimera, Pepinemab, T-Cell therapy

H. Lee Moffitt Cancer Center and Research Institute, Vaccinex Inc.

HER2-positive Breast Cancer

12/25

12/26

NCT03690986: VX15/2503 in Combination with Ipilimumab or Nivolumab in Patients with Head and Neck Cancer

Recruiting

VX15/2503, moAb VX15/2503, Anti-SEMA4D Monoclonal Antibody VX15/2503, Pepinemab, Ipilimumab, BMS-734016, MDX-010, MDX-CTLA4, Yervoy, Nivolumab, BMS-936558, MDX-1106, NIVO, ONO-4538, Opdivo

Emory University, Vaccinex Inc.

Squamous Cell Carcinoma of the Head and Neck

06/25

11/25

VX35 / Vaccinex

No trials found



	Diseases Companies Products Productz Mechanisms of Action Sites